New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Joseph Klein, III Biography and Net Worth

Director of Ionis Pharmaceuticals

Mr. Klein has served as a director of Ionis since December 2005. Mr. Klein is currently managing director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a venture partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002, Mr. Klein was a venture partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as vice president, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems. For over nine years from 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and non-profit entities.

What is Joseph Klein, III's net worth?: The estimated net worth of Joseph Klein, III is at least $578,648.40 as of July 16th, 2024. Mr. Klein, III owns 16,346 shares of Ionis Pharmaceuticals stock worth more than $578,648 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Klein, III may own. Learn More about Joseph Klein, III's net worth.
How do I contact Joseph Klein, III?: The corporate mailing address for Mr. Klein, III and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Joseph Klein, III's contact information.
Has Joseph Klein, III been buying or selling shares of Ionis Pharmaceuticals?: Joseph Klein, III has not been actively trading shares of Ionis Pharmaceuticals during the past quarter. Most recently, Joseph Klein III sold 12,000 shares of the business's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $50.00, for a transaction totalling $600,000.00. Following the completion of the sale, the director now directly owns 16,346 shares of the company's stock, valued at $817,300. Learn More on Joseph Klein, III's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 25 times. They sold a total of 270,830 shares worth more than $13,480,539.63. The most recent insider tranaction occured on November, 12th when EVP Eric Swayze sold 1,194 shares worth more than $45,276.48. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 11/12/2024.

Joseph Klein, III Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/16/2024	Sell	12,000	$50.00	$600,000.00	16,346
5/3/2024	Sell	6,000	$42.71	$256,260.00	16,346
11/15/2023	Sell	2,000	$50.00	$100,000.00	16,346
7/18/2023	Sell	3,555	$42.00	$149,310.00	20,346
1/17/2023	Sell	2,000	$40.00	$80,000.00	16,791
7/15/2022	Sell	1,333	$38.24	$50,973.92	18,791
7/15/2021	Sell	4,334	$35.30	$152,990.20
10/20/2020	Sell	2,889	$46.86	$135,378.54	13,794
12/23/2019	Sell	1,000	$61.87	$61,870.00	13,683
12/16/2019	Sell	1,000	$65.45	$65,450.00	13,683
12/9/2019	Sell	1,000	$63.74	$63,740.00	13,683
12/2/2019	Sell	1,000	$64.08	$64,080.00	13,683
11/25/2019	Sell	812	$62.90	$51,074.80	12,683
11/20/2019	Sell	2,000	$60.00	$120,000.00	13,495
3/29/2018	Sell	2,000	$46.15	$92,300.00	11,939
3/15/2018	Sell	2,000	$51.13	$102,260.00
2/28/2018	Sell	3,000	$51.91	$155,730.00	10,839
2/15/2018	Sell	3,000	$48.99	$146,970.00	11,339
1/30/2018	Sell	3,000	$52.86	$158,580.00
12/29/2017	Sell	3,000	$50.56	$151,680.00
12/29/2017	Sell	3,000	$50.56	$151,680.00	12,939
12/15/2017	Sell	3,000	$51.69	$155,070.00	12,939
11/30/2017	Sell	3,000	$53.55	$160,650.00	12,939
11/15/2017	Sell	2,250	$53.56	$120,510.00	9,377
11/13/2017	Sell	3,000	$55.39	$166,170.00	7,127
11/11/2015	Sell	6,875	$64.18	$441,237.50	5,543
1/24/2014	Sell	10,313	$48.66	$501,830.58	2,313
8/9/2013	Sell	18,750	$28.22	$529,125.00	8,313

Joseph Klein, III Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $35.40

$33.53

$35.60

50 Day Range

MA: $39.01

$33.73

$42.76

2 Week Range

Now: $35.40

$33.33

$54.44

Volume

2,223,069 shs

Average Volume

1,168,921 shs

Market Capitalization

$5.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39